Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Stephanie L. Tzetzo"'
Autor:
Stephanie L. Tzetzo, Elliot D. Kramer, Hemn Mohammadpour, Minhyung Kim, Spencer R. Rosario, Han Yu, Melissa R. Dolan, Chetan C. Oturkar, Brian G. Morreale, Paul N. Bogner, Aimee B. Stablewski, Fernando J. Benavides, Craig M. Brackett, John M.L. Ebos, Gokul M. Das, Mateusz Opyrchal, Michael J. Nemeth, Sharon S. Evans, Scott I. Abrams
Publikováno v:
iScience, Vol 27, Iss 3, Pp 109187- (2024)
Summary: Tissue-resident macrophages (TRMs) are abundant immune cells within pre-metastatic sites, yet their functional contributions to metastasis remain incompletely understood. Here, we show that alveolar macrophages (AMs), the main TRMs of the lu
Externí odkaz:
https://doaj.org/article/b0dead588580421280f878bb0ac7259a
Autor:
Elliot D. Kramer, Stephanie L. Tzetzo, Sean H. Colligan, Mary L. Hensen, Craig M. Brackett, Björn E. Clausen, Makoto M. Taketo, Scott I. Abrams
Publikováno v:
JCI Insight, Vol 8, Iss 8 (2023)
The main cause of malignancy-related mortality is metastasis. Although metastatic progression is driven by diverse tumor-intrinsic mechanisms, there is a growing appreciation for the contribution of tumor-extrinsic elements of the tumor microenvironm
Externí odkaz:
https://doaj.org/article/f762002b983b4170b33a8ba0a4439eaa
Autor:
Kevin H. Eng, Sheila N.J. Sait, Scott I. Abrams, Miranda L. Lynch, Elizabeth A. Griffiths, Joseph Kuechle, Prashant Singh, Jennifer Peresie, Jianmin Wang, Eduardo Cortes Gomez, Ava R. Dimitroff, Kyle Wiatrowski, Pragya Srivastava, Kitty De Jong, Michael J. Nemeth, Stephanie L. Tzetzo
Publikováno v:
Leukemia
The use of immunotherapy to treat patients with myelodysplastic syndromes (MDS) shows promise but is limited by our incomplete understanding of the immunologic milieu. In solid tumors, CD141Hi conventional dendritic cells (CD141Hi cDCs) are necessary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab47b1169360c3636886e2809d37053f
https://doi.org/10.1038/s41375-020-0765-5
https://doi.org/10.1038/s41375-020-0765-5
Publikováno v:
Mol Immunol
The adaptive immune system is essential for host defense against pathogenic challenges, and a major constituent is the CD8(+) cytotoxic T cell. Ordinarily, CD8(+) T cells are endowed with a unique ability to specifically recognize and destroy their t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69b95c0b3dc3762cd2561642c23298d2
https://doi.org/10.1016/j.molimm.2019.12.012
https://doi.org/10.1016/j.molimm.2019.12.012
Autor:
Stephanie L. Tzetzo, Scott I. Abrams
Publikováno v:
Cancer Cell
Macrophages are multi-functional innate immune cells that occupy normal or pathologic tissues, including cancer tissues. The importance of macrophage ontogeny and the transcriptional networks underlying their functional diversity are underappreciated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63f47ec21bf9ad8e202e630d3923cc65
https://pubmed.ncbi.nlm.nih.gov/33798473
https://pubmed.ncbi.nlm.nih.gov/33798473
Autor:
Sejin Chung, Mukund Seshadri, Erik S. Knudsen, Vishnu Kumarasamy, Amanda Ruiz, Scott I. Abrams, Jin Wu, Stephanie L. Tzetzo, Shailender S. Chauhan, Paris Vail, Agnieszka K. Witkiewicz, Jared Sivinski, Jianmin Wang, Ram Nambiar
Publikováno v:
Gut. 70(1)
ObjectiveThis study exploits the intersection between molecular-targeted therapies and immune-checkpoint inhibition to define new means to treat pancreatic cancer.DesignPatient-derived cell lines and xenograft models were used to define the response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a172c6158058f2b9eb5805442b52e7a3
https://pubmed.ncbi.nlm.nih.gov/32571976
https://pubmed.ncbi.nlm.nih.gov/32571976
Autor:
Amanda Ruiz, Mukund Seshadri, Sejin Chung, Paris Vail, Agnieszka K. Witkiewicz, Erik S. Knudsen, Scott I. Abrams, Vishnu Kumarasamy, Stephanie L. Tzetzo, Jianmin Wang
Pancreatic cancer harbors a poor prognosis due to the lack of effective systemic therapies. Here we interrogated means to target key effector pathways down-stream from KRAS. We found that combination treatment with MEK and CDK4/6 inhibitors was effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ba8881f380941deeff6cae688733841
https://doi.org/10.1101/860247
https://doi.org/10.1101/860247
Autor:
Kyle Wiatrowski, Sheila N.J. Sait, Kevin H. Eng, Jennifer Peresie, Miranda L. Lynch, Prashant Singh, Elizabeth A. Griffiths, Stephanie L. Tzetzo, Michael J. Nemeth, Kitty De Jong, Eduardo Cortes Gomez, Jianmin Wang, Pragya Srivastava
Publikováno v:
Blood. 134:1695-1695
Background: Immunotherapeutic approaches for myelodysplastic syndrome (MDS) show promise, but progress is limited by our incomplete understanding of the immunologic milieu. In a recent Phase I trial, we found that MDS patients with higher numbers of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c2f1a8bf783ef258ceb01338fb15059
https://doi.org/10.1182/blood-2019-126220
https://doi.org/10.1182/blood-2019-126220